Hermetica Superfood Encyclopedia
The Short Answer
Bridelia micrantha contains flavonoids such as quercetin and quercetin-3-O-glucoside, phenolics including ellagic acid and gallic acid, triterpenes such as betulinic acid and friedelin, and tannins that collectively mediate antioxidant, antimicrobial, and antiplasmodial activities through free radical scavenging and interference with microbial metabolism. Ethanol leaf extracts demonstrated antiplasmodial activity against Plasmodium falciparum 3D7 and multidrug-resistant Dd2 strains with IC50 values of 19.41 ± 2.93 μg/ml and 37.64 ± 0.77 μg/ml respectively, and DPPH radical scavenging with IC50 as low as 4.617 μg/ml, though all evidence to date is preclinical with no human clinical trials conducted.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordBridelia micrantha benefits
Umthwalume — botanical close-up
Health Benefits
**Antiplasmodial Activity**
Ethanol and aqueous leaf extracts inhibit both chloroquine-sensitive (3D7, IC50 31.65 ± 0.79 μg/ml) and chloroquine-resistant (Dd2, IC50 37.64 ± 0.77 μg/ml) Plasmodium falciparum strains in vitro, with flavonoids, tannins, and phenolics implicated as the primary bioactive agents interfering with parasite metabolism.
**Antioxidant Protection**
Ethanol leaf extracts exhibit potent DPPH free radical scavenging activity (IC50 4.617 μg/ml) and ferric reducing antioxidant power (FRAP IC50 63.78–69.32 μg/ml), attributed to electron-donating polyphenols including quercetin, gallic acid, and ellagic acid that neutralize reactive oxygen species.
**Antimicrobial Action Against Bacterial Pathogens**
Methanol leaf extracts produce zones of inhibition of 19–20 mm against Staphylococcus aureus and Salmonella typhi, suggesting that tannins and flavonoids disrupt bacterial cell membrane integrity and inhibit key enzymatic processes in susceptible organisms.
**Anti-Inflammatory Effects**
Phytochemicals including betulinic acid, friedelin, and quercetin found in Bridelia micrantha are recognized inhibitors of pro-inflammatory pathways, with traditional use for pain and inflammatory conditions supported by the documented presence of these bioactive classes, though in vivo anti-inflammatory studies specific to this species remain limited.
**Wound Healing Support**
Traditional preparation of aqueous bark and leaf decoctions applied topically for wound care is consistent with the known astringent and antimicrobial properties of tannins and ellagic acid, which can reduce microbial colonization of wounds and promote tissue contraction.
**Hepatoprotective Potential**
Ethnobotanical records document use for liver protection in central African traditional medicine, with triterpenes such as betulinic acid known in related species to modulate hepatic oxidative stress and inflammatory mediators, though direct in vitro or in vivo hepatoprotective assays specific to B. micrantha have not been published.
**Antiparasitic and Anthelmintic Use**
Traditional healers in Cameroon and surrounding regions use bark and root decoctions to treat helminth infections and schistosomiasis, consistent with the saponin and tannin content of the plant, which are known in other medicinal plants to impair parasitic motility and tegumental integrity.
Origin & History
Natural habitat
Bridelia micrantha is native to sub-Saharan Africa, distributed across central, eastern, and southern Africa including Cameroon, South Africa, and surrounding regions, typically growing in woodland margins, riverine forests, and disturbed forest edges at low to mid elevations. The tree favors well-drained soils in tropical and subtropical climates with seasonal rainfall. It has not been formally cultivated for commercial purposes and is harvested from wild populations by traditional healers who use the bark, leaves, roots, and fruits.
“Bridelia micrantha has been used across sub-Saharan Africa — with particularly well-documented use in Cameroon and southern Africa — as a multipurpose medicinal tree whose bark, leaves, roots, and fruits feature in the treatment of malaria, helminthiasis, schistosomiasis, diarrhea, convulsions, pain, diabetes, and liver disease, representing one of the most medicinally diverse trees in African ethnobotanical records. In South African traditional healing contexts, the Zulu name Umthwalume reflects cultural familiarity with the plant as a resource for wound management and eye care, with healers preparing aqueous leaf and bark washes for topical application to infected eyes and skin lesions. Preparation methods in traditional contexts involve boiling plant material to create decoctions consumed orally or applied topically, or direct application of fresh plant material, reflecting indigenous pharmacological knowledge of water-soluble bioactive extraction. The breadth of its traditional applications across geographically distant African cultures — from Cameroon in the west to South Africa in the south — underscores its historical significance as a cornerstone of African traditional medicine and provides the ethnobotanical rationale driving modern phytochemical investigation of this species.”Traditional Medicine
Scientific Research
The entirety of available scientific evidence for Bridelia micrantha consists of in vitro assays and phytochemical screenings, with no published human clinical trials, randomized controlled trials, or systematic reviews identified as of the current literature search. Antiplasmodial activity has been quantified by IC50 measurements against P. falciparum 3D7 and Dd2 strains, with resistance indices of 1.18–1.9 relative to chloroquine-resistant strains, providing a preliminary signal of pharmacological relevance but without in vivo efficacy confirmation in animal models or dose-response studies in higher organisms. Antioxidant capacity has been assessed across multiple extract preparations (aqueous, ethanol) using DPPH and FRAP assays, and antibacterial activity has been measured via disk diffusion zones of inhibition; these assays, while standardized in vitro tools, do not establish bioavailability, systemic efficacy, or clinical relevance in humans. Cytotoxicity evaluations against RAW 264.7 macrophages and red blood cells at tested concentrations showed no significant toxicity, supporting preliminary safety but falling far short of the evidence required to establish therapeutic dosing or clinical recommendations.
Preparation & Dosage
Traditional preparation
**Aqueous Decoction (Traditional)**
Bark or leaves are boiled in water for 15–30 minutes to prepare decoctions used orally for malaria, diarrhea, and systemic infections; no standardized volume or dose has been established in clinical research.
**Topical Leaf Poultice (Traditional)**
Fresh or dried leaves are crushed and applied directly to wounds or used as a wash for eye infections in traditional practice across southern and central Africa; no clinical dosing parameters exist.
**Ethanol Extract (Research Use)**
Ethanol leaf extracts have been prepared at variable concentrations (typically 10–200 μg/ml) for in vitro assays; no human-relevant dose has been derived from these studies.
**Methanol Extract (Research Use)**
Methanol leaf extracts demonstrating 19–20 mm inhibition zones against S. aureus and S. typhi were prepared at concentrations used exclusively in laboratory disk diffusion assays, with no translatable oral or topical dose for humans.
**Standardization**
No commercial standardized extract exists; no marker compound standardization (e.g., quercetin percentage) has been established or validated for this plant.
**Clinical Dose**
No safe or effective clinical dose has been determined; practitioners should not administer extracts outside of formally supervised ethnomedicinal or research contexts until human pharmacokinetic and toxicological data are available.
Nutritional Profile
Bridelia micrantha is not consumed as a food source and has not been characterized as a nutritional ingredient; no macronutrient or micronutrient composition data (protein, carbohydrate, fat, vitamins, minerals) have been published for any plant part. The phytochemical profile — primarily assessed from bark, leaf, and fruit extracts — identifies flavonoids (quercetin, quercetin-3-O-glucoside, catechin), phenolic acids (gallic acid, ellagic acid, caffeic acid), triterpenes (betulinic acid, friedelin, acacic acid lactone), alkaloids, saponins, tannins, sterols, and fatty acids including palmitic acid and naphthalene derivatives as the primary secondary metabolites of pharmacological relevance. Quantitative concentrations of individual phytochemicals within plant material have not been reported in peer-reviewed literature; activity is inferred from extract-level IC50 values rather than isolated compound concentrations. Bioavailability of key polyphenols such as quercetin and ellagic acid from this plant matrix has not been studied; general pharmacokinetic data from other botanical sources suggest that polyphenol bioavailability is significantly influenced by the food matrix, gut microbiota metabolism, and the presence of complexing agents such as tannins, which may limit absorption of co-occurring compounds.
How It Works
Mechanism of Action
The antioxidant activity of Bridelia micrantha extracts operates primarily through electron donation and hydrogen atom transfer by polyphenolic compounds — particularly quercetin, gallic acid, ellagic acid, and catechin — which quench DPPH radicals and reduce ferric iron (FRAP assay), thereby interrupting lipid peroxidation chain reactions and neutralizing reactive oxygen species. Antiplasmodial activity, evidenced by IC50 values of 19.41–37.64 μg/ml against P. falciparum strains, is hypothesized to involve flavonoid and tannin-mediated interference with the parasite's hemoglobin digestion pathway and mitochondrial electron transport, though the precise molecular targets within the parasite have not been experimentally confirmed in published studies. Antimicrobial effects against S. aureus and S. typhi are attributed to tannin-mediated precipitation of bacterial membrane proteins and disruption of cell wall integrity, while alkaloids may contribute to nucleic acid intercalation in susceptible organisms. The triterpene betulinic acid, documented in the phytochemical profile, is known from other botanical contexts to induce mitochondria-dependent apoptosis and inhibit NF-κB signaling, which may partly underpin both antimicrobial and anti-inflammatory effects, but pathway-specific mechanistic studies in Bridelia micrantha have been explicitly identified in the literature as a research gap requiring future investigation.
Clinical Evidence
No human clinical trials have been conducted on Bridelia micrantha or its extracts for any health indication, including wound healing, eye infections, malaria, or antimicrobial applications. The available evidence base is restricted to in vitro cell-based and cell-free assays, with quantified outcomes limited to IC50 values for DPPH radical scavenging (4.617 μg/ml for ethanol leaf extract), FRAP values, and antiplasmodial IC50 measurements against P. falciparum strains; no effect sizes, confidence intervals, or sample sizes from human cohorts exist. Traditional use across sub-Saharan Africa — particularly in Cameroon — provides ethnobotanical plausibility for wound healing, antimicrobial, and antiparasitic applications, but ethnobotanical records cannot substitute for controlled clinical evidence. Confidence in any clinical benefit recommendation is therefore very low, and this ingredient should be regarded as a candidate for future preclinical animal studies and, if warranted, early-phase human safety trials rather than an evidence-supported supplement.
Safety & Interactions
Preclinical cytotoxicity assessments indicate that aqueous and ethanol extracts of Bridelia micrantha are non-cytotoxic to RAW 264.7 macrophages and do not cause hemolysis of red blood cells at concentrations tested in vitro, and mild or no irritation was observed in rodent ocular and dermal exposure models, providing a preliminary safety signal but not establishing a safe human dose. No human adverse event data, formal toxicology studies (acute, subacute, or chronic), drug interaction studies, or pharmacokinetic data have been published, meaning that drug interactions with anticoagulants, antidiabetics, antiparasitic agents, or immunosuppressants cannot be excluded and should be considered a significant unknown risk. Contraindications have not been formally established; however, pregnant and lactating women should avoid use in the absence of any reproductive safety data, as saponins and alkaloids present in the plant have the potential for uterotonic or fetotoxic effects in insufficiently studied botanical matrices. Maximum safe doses for human consumption have not been determined, and self-administration of crude extracts or decoctions outside of supervised traditional healing contexts is not supported by existing evidence.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Bridelia micranthaUmthwalumeCoastal golden-leafBridelia micrantha (Hochst.) Baill.
Frequently Asked Questions
What is Umthwalume used for in traditional African medicine?
Umthwalume (Bridelia micrantha) is used across sub-Saharan Africa — particularly in Cameroon and South Africa — to treat malaria, diarrhea, helminth infections, wounds, eye infections, pain, convulsions, diabetes, schistosomiasis, and liver disease. Healers prepare aqueous decoctions from bark and leaves for oral administration and topical washes, with the Zulu tradition specifically using leaf preparations for wound care and eye infections. These uses are ethnobotanically well-documented but have not been validated in human clinical trials.
Does Bridelia micrantha have scientific evidence for fighting malaria?
In vitro studies show that ethanol leaf extracts of Bridelia micrantha inhibit both chloroquine-sensitive (P. falciparum 3D7, IC50 19.41–31.65 μg/ml) and chloroquine-resistant (Dd2, IC50 37.64 μg/ml) strains of the malaria parasite, with resistance indices of 1.18–1.9. These results are promising at the preclinical level and suggest flavonoids, tannins, and phenolics as the likely active agents, but no animal efficacy studies or human clinical trials have been conducted. The antiplasmodial activity remains far below that of the reference drug artemisinin (IC50 0.034–0.043 μM) and should not be interpreted as a substitute for established antimalarial treatment.
Is Umthwalume safe to use?
Preclinical safety assessments indicate that Bridelia micrantha aqueous and ethanol extracts are non-cytotoxic to immune cells (RAW 264.7 macrophages) and do not cause red blood cell hemolysis at concentrations tested in laboratory settings, and mild or no irritation was observed in rodent eye and skin models. However, no human safety trials, formal toxicology studies, or drug interaction data exist, so the full safety profile in humans is unknown. Pregnant and breastfeeding women should avoid use, and individuals on medications including antimalarials, antidiabetics, or anticoagulants should consult a healthcare provider before using any preparations of this plant.
What are the key active compounds in Bridelia micrantha?
Phytochemical analyses of Bridelia micrantha identify flavonoids (quercetin, quercetin-3-O-glucoside, catechin, caffeic acid), phenolic acids (gallic acid, ellagic acid), triterpenes (betulinic acid, friedelin, acacic acid lactone), alkaloids, tannins, saponins, sterols, and fatty acids including palmitic acid as the major secondary metabolite classes found in bark, leaves, and fruits. These compounds are broadly recognized across botanical pharmacology for antioxidant, antimicrobial, and anti-inflammatory activities. Quantitative concentrations of individual compounds within the plant material have not been published; pharmacological activity has been characterized only at the crude extract level via IC50 measurements.
What is the recommended dose of Umthwalume supplement?
No established or clinically validated dose exists for Umthwalume (Bridelia micrantha) in any form — oral, topical, or supplemental. Research to date has used aqueous, ethanol, and methanol extracts exclusively in laboratory in vitro assays at concentrations of 10–200 μg/ml, and no human pharmacokinetic studies have been conducted to translate these laboratory concentrations into safe and effective human doses. There are no commercial standardized supplements available, and self-administration of crude preparations outside of traditional supervised healing contexts is not recommended pending formal clinical investigation.
Does Umthwalume interact with antimalarial medications like chloroquine or artemisinin?
While Umthwalume (Bridelia micrantha) shows antiplasmodial activity in vitro against both chloroquine-sensitive and chloroquine-resistant Plasmodium falciparum strains, there is limited clinical data on potential interactions with prescription antimalarial drugs. The herb's flavonoids and phenolics may theoretically affect drug metabolism, so concurrent use with antimalarials should be discussed with a healthcare provider. It should not be used as a replacement for established antimalarial treatments without medical supervision.
How do the different extraction methods of Bridelia micrantha affect its antimalarial potency?
Both ethanol and aqueous extracts of Umthwalume leaves demonstrate antiplasmodial activity, with ethanol extracts showing slightly lower IC50 values against resistant strains (37.64 ± 0.77 μg/ml for Dd2) compared to aqueous preparations. Ethanol extraction appears to concentrate flavonoids, tannins, and phenolics more effectively, which are the primary compounds responsible for inhibiting parasite metabolism. The choice of extraction method may influence the supplement's potency, though both forms show measurable antimalarial effects in laboratory studies.
What populations would benefit most from Umthwalume supplementation based on current research?
Individuals living in malaria-endemic regions or those at risk of chloroquine-resistant Plasmodium falciparum infection may benefit most from Umthwalume, given its demonstrated antiplasmodial activity against both drug-sensitive and drug-resistant parasite strains in vitro. The herb's traditional use in African medicine for malaria treatment, combined with its laboratory-verified bioactivity, suggests potential value as an adjunctive approach in endemic areas. However, clinical trial data in human populations remains limited, and supplementation should complement rather than replace proven antimalarial therapies.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w umthwalume-bridelia-micrantha curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
